Description: Anatara Lifesciences Ltd is an Australia-based company focused on developing oral solutions for gastrointestinal diseases in production animals and humans and the development and commercialization of Detach, a non-antibiotic therapy that prevents and treats diarrhea (scour) in piglets. Detach is a modified release formulation of BromelainRx, a natural extract from pineapple stems. Detach helps in address the overuse of antibiotics in animals. It is formulated with various ingredients to allow oral administration and delivery to the small intestine. The Company is focused on developing Detach for pigs in Australia and then expanding the program to Europe and the United States. The Company is also developing a similar version of Detach to prevent diarrhea in humans. The Company is seeking to collaborate with pharmaceutical/biotechnology companies for clinical development and commercialization of a similar version of Detach for human application in travelers and military personnel.
Home Page: anataralifesciences.com
ANR Technical Analysis
62 Lygon Street
Carlton,
VIC
3053
Australia
Phone:
61 3 9824 5454
Officers
| Name | Title |
|---|---|
| Dr. David Lionel Brookes FACRRM, FAICD, MBBS | Exec. Chairman |
| Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. | Chief Operations Officer |
| Jane Lowe | Managing Director of IR Department |
| Mr. Simon Erskine | Chief Devel. Officer |
| Dr. Stephen Denaro AGIA, BCom, CA, GradDipApp CG, MAICD | Company Sec. |
| Ms. Hayley van der Meer B Biomed Sc, Grad Dip Marketing Management | Commercial Mang. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4897 |
| Price-to-Sales TTM: | 6.3137 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |